Next-Generation RNA Therapeutics Market

How Fast Is the Next-Generation RNA Therapeutics Market Growing?

The global next-generation RNA therapeutics market size is expected to be valued at US$ 8.78 billion in 2026 and projected to reach US$ 24.37 billion by 2033, growing at a CAGR of 15.7% between 2026 and 2033.

Between 2020 and 2025, the market grew at a CAGR of about 18.4%, as approved siRNA and antisense drugs for rare genetic, neurological, and cardiovascular diseases gained wider use. Three factors now drive growth: expansion from rare diseases into large cardiovascular and metabolic indications, better delivery technologies that reach tissues beyond the liver, and emerging modalities such as self-amplifying RNA, circular RNA, and RNA editing. The market is moving toward long-acting drugs dosed a few times a year, which improves adherence and supports premium pricing. Large pharmaceutical companies are investing heavily through acquisitions and partnerships.

• By Molecule Type: Antisense Oligonucleotides held 45.2% share in 2026, while Emerging Modalities are projected to expand at a 31.4% CAGR through 2033, driven by self-amplifying RNA, circular RNA, and RNA editing programs.
• By Therapeutic Area: Neurological Disorders held 34.6% share in 2026, while Cardiovascular & Metabolic Diseases are projected to expand at a 21.3% CAGR through 2033, driven by long-acting cholesterol and amyloidosis treatments.
• By Delivery Platform: GalNAc Conjugates held 48.3% share in 2026, while Antibody & Peptide Conjugates are projected to expand at a 27.5% CAGR through 2033, driven by delivery to muscle and other tissues.
• By Region: North America held 61.5% share in 2026, while Asia Pacific is projected to expand at a 19.8% CAGR through 2033, driven by biotech investment in China and Japan.

Two drivers carry the strongest influence on next-generation RNA therapeutics demand during the forecast period.

Cardiovascular Approvals Are Driving Next-Generation RNA Therapeutics Growth

Expansion into large cardiovascular and metabolic indications is the strongest driver of next-generation RNA therapeutics growth. RNA drugs are moving beyond small rare disease populations into conditions that affect millions of patients.

The mechanism is gene silencing of disease-causing proteins in the liver with infrequent dosing. In March 2025, the U.S. Food and Drug Administration approved Alnylam’s Amvuttra for transthyretin amyloid cardiomyopathy, a large and underdiagnosed heart disease. Novartis’s Leqvio, an siRNA dosed twice yearly, lowers LDL cholesterol in patients with cardiovascular disease. In December 2024, the FDA approved Ionis’s Tryngolza for familial chylomicronemia syndrome, a triglyceride disorder. Late-stage programs target lipoprotein(a), hypertension, and severe hypertriglyceridemia. Twice-yearly or quarterly injections improve adherence compared with daily pills, making RNA interference attractive for chronic cardiovascular prevention and expanding the treated population.

Delivery and Chemistry Advances Are Expanding Next-Generation RNA Therapeutics

Advances in delivery technologies and chemical modifications are expanding next-generation RNA therapeutics to new tissues and diseases. Early RNA drugs mainly reached the liver or required injection into the spinal fluid.

The cause is innovation in conjugates, lipid nanoparticles, and oligonucleotide chemistry. GalNAc conjugates deliver siRNA and antisense drugs efficiently to liver cells with subcutaneous injection. New antibody-oligonucleotide conjugates and peptide conjugates reach muscle, heart, and the central nervous system. In October 2025, Novartis agreed to acquire Avidity Biosciences, a developer of antibody-oligonucleotide conjugates for neuromuscular diseases, for about US$ 12 billion. Chemical modifications extend drug activity to months. Lipid nanoparticles enable mRNA therapeutics and gene editing. Self-amplifying RNA reduces dose needs, while RNA editing corrects genetic errors without permanently changing DNA, opening new treatment possibilities.

Two restraints limit how quickly next-generation RNA therapeutics grow.

High Prices and Reimbursement Pressure Limit Next-Generation RNA Therapeutics Access

High prices and reimbursement pressure limit access to next-generation RNA therapeutics. Many RNA drugs for rare diseases cost hundreds of thousands of dollars per patient each year, straining payer budgets.

The specific causes are small patient populations, high development costs, and new pricing policies. Rare disease drugs must recover research costs from limited patient numbers, which leads to very high list prices. As RNA drugs move into larger indications, payers demand lower prices, outcomes data, and cost-effectiveness evidence. In the United States, the Inflation Reduction Act allows Medicare to negotiate prices, and oligonucleotides were initially treated like small molecules with a shorter exemption period than biologics, which concerned developers. Health technology assessment bodies in Europe, such as NICE in England, may restrict use to narrower groups. These pressures can slow uptake and affect investment decisions.

Manufacturing and Delivery Limits Constrain Next-Generation RNA Therapeutics

Manufacturing complexity and delivery limits constrain next-generation RNA therapeutics. Producing oligonucleotides at large scale is costly, and many tissues remain hard to reach.

The underlying causes are chemistry and biology. Oligonucleotides are made by solid-phase synthesis that uses large amounts of solvents such as acetonitrile and expensive modified building blocks, generating significant waste. Scaling production for large cardiovascular markets requires major new capacity, which contract manufacturers such as Agilent, Nitto Avecia, and ST Pharm are building. Delivery beyond the liver remains difficult because RNA molecules are large, charged, and quickly degraded. Lipid nanoparticles can trigger immune reactions, and some antisense drugs have caused kidney or platelet side effects. Long-term safety data are still limited for newer modalities, so regulators require careful long-term patient monitoring.

RNA Editing and Self-Amplifying RNA Open a New Therapeutic Revenue Pool

RNA editing and self-amplifying RNA open a new therapeutic revenue pool in the next-generation RNA therapeutics market. These modalities could treat diseases that current siRNA and antisense drugs cannot address.

Companies with novel platforms and strong delivery capabilities can capture this demand. RNA editing uses the body’s own enzymes to correct single-letter genetic errors in RNA, offering a reversible alternative to DNA editing. In October 2024, Wave Life Sciences reported the first clinical proof of RNA editing in alpha-1 antitrypsin deficiency. Self-amplifying RNA produces more protein from smaller doses; Arcturus and CSL gained European approval of the self-amplifying COVID-19 vaccine Kostaive in February 2025. Circular RNA offers longer-lasting protein expression. Rare disease patients, oncology, and vaccine programs are early markets, attracting partnerships with large pharmaceutical companies.

Extrahepatic Delivery Opens a Neuromuscular and CNS Revenue Pool

Extrahepatic delivery opens a large revenue pool for next-generation RNA therapeutics in neuromuscular, cardiac, and central nervous system diseases. Most approved RNA drugs target the liver, leaving many serious diseases untreated.

Companies developing conjugates that reach muscle, brain, and other tissues can capture this opportunity. Antibody-oligonucleotide conjugates target receptors on muscle cells to treat myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. Novartis’s planned acquisition of Avidity Biosciences shows strong interest in this area. Intrathecal antisense oligonucleotides such as Biogen’s Spinraza already treat spinal muscular atrophy, and new programs target Alzheimer’s, Huntington’s, and amyotrophic lateral sclerosis. Patients with neuromuscular and neurodegenerative diseases, neurologists, and specialty treatment centers are key customers. These diseases have high unmet need, few effective alternatives, and strong patient advocacy, which support premium pricing.

By Molecule Type: Antisense Oligonucleotides Lead While Emerging Modalities Gain Momentum

Antisense Oligonucleotides held 45.2% share in 2026. Approved antisense drugs such as Biogen’s Spinraza, Ionis’s Wainua and Tryngolza, and Sarepta’s exon-skipping therapies treat spinal muscular atrophy, transthyretin amyloidosis, Duchenne muscular dystrophy, and lipid disorders. Their long clinical history and broad pipeline support leadership.

Emerging Modalities are the fastest-growing molecule type, expanding at a 31.4% CAGR through 2033. This group includes mRNA therapeutics, self-amplifying RNA, circular RNA, and RNA editing, which can replace missing proteins, produce therapeutic proteins, or correct genetic errors. Early approvals and clinical data are attracting investment. siRNA drugs such as Amvuttra, Leqvio, and Givlaari form a fast-growing established segment. For the market, emerging modalities expand the range of treatable diseases and support long-term growth beyond gene silencing.

By Therapeutic Area: Neurological Disorders Lead While Cardiovascular & Metabolic Diseases Grow Fastest

Neurological Disorders held 34.6% share in 2026. Drugs for spinal muscular atrophy, hereditary transthyretin amyloidosis with polyneuropathy, Duchenne muscular dystrophy, and amyotrophic lateral sclerosis generate significant revenue. Few alternative treatments exist for many of these conditions.

Cardiovascular & Metabolic Diseases are the fastest-growing therapeutic area, expanding at a 21.3% CAGR through 2033. Amvuttra’s approval for transthyretin amyloid cardiomyopathy and Leqvio’s use for high cholesterol bring RNA drugs to much larger populations. Programs targeting lipoprotein(a), triglycerides, and hypertension could reach millions of patients. Infrequent dosing suits chronic prevention in primary care. Rare genetic diseases, oncology, infectious diseases, and ocular disorders remain important areas. For the market, cardiovascular growth shifts RNA therapeutics from niche rare diseases toward mainstream medicine.

By Delivery Platform: GalNAc Conjugates Lead While Antibody & Peptide Conjugates Grow Fastest

GalNAc Conjugates held 48.3% share in 2026. This platform attaches sugar molecules that bind receptors on liver cells, allowing small subcutaneous doses of siRNA or antisense drugs to reach the liver efficiently. Most recent cardiovascular and metabolic RNA drugs use GalNAc technology.

Antibody & Peptide Conjugates are the fastest-growing delivery platform, expanding at a 27.5% CAGR through 2033. These approaches attach RNA molecules to antibodies or peptides that target receptors on muscle, heart, or brain cells. Clinical programs from Avidity Biosciences, Dyne Therapeutics, and PepGen target neuromuscular diseases. Lipid nanoparticles remain important for mRNA and RNA editing, while naked chemically modified oligonucleotides serve intrathecal and ocular uses. For the market, conjugate growth opens tissues beyond the liver and creates new high-value treatment categories.

Which Region Is Leading the Next-Generation RNA Therapeutics Market?

North America is leading the next-generation RNA therapeutics market with a 61.5% share in 2026. The United States hosts most leading RNA companies, including Alnylam, Ionis, Arrowhead, Sarepta, Biogen, and Moderna. The FDA has approved most RNA drugs first, and high drug prices support strong revenue. Venture capital and pharmaceutical partnerships fund many startups in Boston, San Diego, and San Francisco. Rare disease incentives such as orphan drug exclusivity support development. Canada adds research strength. One change shaping the region is the expansion of RNA drugs into large cardiovascular markets.

Europe Expands Next-Generation RNA Therapeutics Through Approvals and Biotech Innovation

Europe is a major next-generation RNA therapeutics market with strong research and regulatory pathways. The European Medicines Agency has approved many siRNA and antisense drugs, and Germany, France, the United Kingdom, and Italy are key markets. Novartis in Switzerland markets Leqvio widely, and BioNTech and CureVac in Germany develop mRNA therapies. Silence Therapeutics in the United Kingdom develops siRNA drugs. Health technology assessments and price controls limit uptake for some therapies, and England’s NHS has used population-level agreements to expand access to Leqvio. One opportunity is population-wide cardiovascular programs using long-acting siRNA.

Which Region Is Growing Fastest in the Next-Generation RNA Therapeutics Market?

Asia Pacific is growing fastest in the next-generation RNA therapeutics market at a 19.8% CAGR through 2033. Japan has early approvals of RNA drugs and approved the self-amplifying COVID-19 vaccine Kostaive in 2023. China has fast-growing RNA biotech companies such as Suzhou Ribo Life Science and strong government support for innovative drugs. South Korea hosts oligonucleotide manufacturers such as ST Pharm and developers such as Olix Pharmaceuticals. Large aging populations with cardiovascular disease create demand. Pricing and reimbursement remain key barriers. One opportunity is licensing deals between Asian biotechs and Western pharmaceutical companies.

Latin America Gains Access to Next-Generation RNA Therapeutics Through Rare Disease Programs

Latin America is an emerging market where rare disease programs and regulatory approvals expand access to next-generation RNA therapeutics. Brazil has a large population with hereditary transthyretin amyloidosis linked to Portuguese ancestry, creating demand for RNA drugs. ANVISA in Brazil and COFEPRIS in Mexico have approved several RNA therapies. Argentina and Colombia use them through specialty programs at major reference hospitals, often supported by patient advocacy groups and manufacturer access programs. Key barriers include very high prices, limited public reimbursement, and reliance on court orders for access. One opportunity is cardiovascular RNA drugs as prices fall and evidence grows.

Middle East & Africa Develops Next-Generation RNA Therapeutics Access for Genetic Diseases

Middle East & Africa is a developing market where genetic disease burden and healthcare investment drive interest in next-generation RNA therapeutics. Saudi Arabia and other Gulf countries have high rates of inherited diseases linked to consanguinity, creating need for therapies such as those for spinal muscular atrophy. National genome and newborn screening programs help identify patients early. The United Arab Emirates and Saudi Arabia are investing in advanced hospitals. In Africa, access remains limited to private and academic centers. Key barriers include high cost, diagnosis gaps, and limited genetic testing. One opportunity is genetic screening linked to RNA therapy access.

The next-generation RNA therapeutics market is highly concentrated. Alnylam, Ionis, Novartis, Biogen, and Sarepta hold most current revenue through approved siRNA and antisense drugs. Arrowhead, Silence Therapeutics, Dicerna, now part of Novo Nordisk, Wave Life Sciences, Avidity Biosciences, Dyne Therapeutics, and Arcturus develop new programs, while large companies such as Roche, AstraZeneca, Eli Lilly, and Novo Nordisk invest through partnerships. High technical, regulatory, and intellectual property barriers protect leaders.

Companies compete on delivery technology, durability of effect, safety, dosing frequency, manufacturing scale, and clinical evidence. Platform companies such as Arrowhead license their technologies widely, generating milestone and royalty revenue. Large pharmaceutical partners bring commercial reach for broad cardiovascular indications. Chinese biotechs are increasingly licensing siRNA candidates to Western companies, adding new competitors and lowering development costs for partners.

Strategic moves show how competition is changing. In December 2024, Ionis gained FDA approval for Tryngolza, its first independently launched drug. In March 2025, Alnylam won FDA approval for Amvuttra in transthyretin amyloid cardiomyopathy, opening a much larger market. In October 2025, Novartis agreed to acquire Avidity Biosciences for about US$ 12 billion to expand into neuromuscular RNA therapies. These moves show competition shifting toward larger indications and delivery beyond the liver.

Three clear themes shape vendor strategy. First, companies are moving into cardiovascular and metabolic diseases. Second, they are investing in extrahepatic delivery platforms. Third, they are building manufacturing capacity for large-volume products.

Next-Generation RNA Therapeutics Market Industry Leaders

• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Novartis
• Biogen
• Sarepta Therapeutics

Recent Industry Developments

October 2025: Novartis agreed to acquire Avidity Biosciences for about US$ 12 billion - expands into antibody-oligonucleotide conjugates for neuromuscular diseases.

March 2025: The FDA approved Alnylam’s Amvuttra for transthyretin amyloid cardiomyopathy - brings siRNA into a large cardiovascular market.

February 2025: Arcturus and CSL received European approval for Kostaive - first self-amplifying mRNA vaccine approved in Europe.

December 2024: The FDA approved Ionis’s Tryngolza for familial chylomicronemia syndrome - strengthens antisense in metabolic diseases.

October 2024: Wave Life Sciences reported the first clinical proof of RNA editing - validates a new therapeutic modality.

This report covers RNA-based medicines beyond first-generation approaches, including siRNA, antisense oligonucleotides, mRNA therapeutics, self-amplifying RNA, circular RNA, and RNA editing therapies, along with their delivery platforms, used for neurological, cardiovascular, metabolic, rare genetic, and other diseases. It excludes pandemic-contract mRNA COVID-19 vaccines, research reagents, and DNA-based gene therapies. The base year is 2025, and the forecast period runs from 2026 to 2033. All values are expressed in US$ Billion.

Molecule Type

• Antisense Oligonucleotides
• siRNA
• Emerging Modalities

Therapeutic Area

• Neurological Disorders
• Cardiovascular & Metabolic Diseases
• Rare Genetic Diseases
• Oncology
• Others

Delivery Platform

• GalNAc Conjugates
• Lipid Nanoparticles
• Antibody & Peptide Conjugates
• Naked & Chemically Modified Oligonucleotides

Regions

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa